Skip to main content
. 2012 Jun 29;109(29):11818–11823. doi: 10.1073/pnas.1205995109

Fig. 6.

Fig. 6.

PI3K inhibition decreases FAS and glycolysis in PEL cells. (A) Treatment of cells for 72 h with a noncytotoxic dose (1 μM) of LY294002 reduces the rate of glycolysis in both PEL (P ≤ 0.01) and primary B cells (P ≤ 0.01). Error bars are ± SEM. (B) LY294002 treatment significantly reduces FAS in PEL (P ≤ 0.01) but does not alter the already low rate of FAS in primary B cells. Error bars are ± SEM. (C) Treatment with LY294002 leads to a dose-dependent decrease in expression of FASN in BCBL-1 (Left), BC-3 (Right), and VG-1 (Center) PEL cells, with a concurrent decrease in pAKT.